Mong-Hong Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1761233/publications.pdf

Version: 2024-02-01

85 papers	8,439 citations	76196 40 h-index	60497 81 g-index
90 all docs	90 docs citations	90 times ranked	10283 citing authors

#	Article	IF	Citations
1	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 1994, 78, 59-66.	13.5	2,065
2	Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology, 2001, 3, 245-252.	4.6	999
3	Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 1994, 372, 570-573.	13.7	911
4	Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biology and Medicine, 2014, 11, 1-19.	1.4	345
5	Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression. Journal of Biological Chemistry, 2000, 275, 23106-23112.	1.6	264
6	14-3-3Ïƒ Positively Regulates p53 and Suppresses Tumor Growth. Molecular and Cellular Biology, 2003, 23, 7096-7107.	1.1	216
7	Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterology Report, 2018, 6, 1-12.	0.6	192
8	Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nature Communications, 2016, 7, 13007.	5.8	186
9	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle, 2012, 11, 785-796.	1.3	169
10	Aurora B kinase phosphorylates and instigates degradation of p53. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1513-22.	3.3	155
11	Roles of COP9 signalosome in cancer. Cell Cycle, 2011, 10, 3057-3066.	1.3	124
12	Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27. Journal of Biological Chemistry, 2000, 275, 24735-24739.	1.6	113
13	Regulators of G1 cyclin-dependent kinases and cancers. Cancer and Metastasis Reviews, 2003, 22, 435-449.	2.7	104
14	Regulation of the p53-MDM2 pathway by 14-3-3 Ïƒ and other proteins. Seminars in Cancer Biology, 2006, 16, 225-234.	4.3	100
15	Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. Journal of Clinical Investigation, 2011, 121, 851-865.	3.9	99
16	Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterology, 2013, 13, 67.	0.8	94
17	Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation. American Journal of Pathology, 2009, 175, 400-411.	1.9	89
18	Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptorâ€“Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	87

#	Article	IF	Citations
19	A hypoxia-responsive TRAF6â€“ATMâ€“H2AX signalling axis promotes HIF1Î± activation, tumorigenesis andÂmetastasis. Nature Cell Biology, 2017, 19, 38-51.	4.6	83
20	E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17493-17498.	3.3	80
21	Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Molecular Cancer, 2010, 9, 42.	7.9	80
22	DNA Damageâ€“Induced Protein 14-3-3 Ïƒ Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer. Cancer Research, 2006, 66, 3096-3105.	0.4	79
23	A case-control study of unilateral and bilateral breast carcinoma patients. Cancer, 2001, 91, 1845-1853.	2.0	76
24	Roles for CSN5 in control of p53/MDM2 activities. Journal of Cellular Biochemistry, 2008, 103, 1219-1230.	1.2	74
25	Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene, 2005, 24, 1924-1935.	2.6	72
26	The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Journal of Cellular and Molecular Medicine, 2011, 15, 825-836.	1.6	70
27	Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. Cancer Research, 2015, 75, 4708-4717.	0.4	69
28	CSN6 drives carcinogenesis by positively regulating Myc stability. Nature Communications, 2014, 5, 5384.	5.8	67
29	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell, 2015, 28, 183-197.	7.7	67
30	The cell cycle regulator 14-3-3Ïƒ opposes and reverses cancer metabolic reprogramming. Nature Communications, 2015, 6, 7530.	5.8	65
31	Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 1476-1487.	1.9	60
32	14-3-3Ïƒ Exerts Tumor-Suppressor Activity Mediated by Regulation of COP1 Stability. Cancer Research, 2011, 71, 884-894.	0.4	55
33	p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle, 2012, 11, 3433-3442.	1.3	54
34	p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene, 2001, 20, 3695-3702.	2.6	51
35	14-3-3Ïƒ, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Molecular Cancer Therapeutics, 2006, 5, 253-260.	1.9	48
36	ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer. Cell Research, 2020, 30, 163-178.	5.7	48

#	Article	IF	Citations
37	Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Molecular Carcinogenesis, 2001, 30, 169-175.	1.3	45
38	Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle, 2012, 11, 2314-2326.	1.3	44
39	Interferon-Inducible Protein IFIXÎ±1 Functions as a Negative Regulator of HDM2. Molecular and Cellular Biology, 2006, 26, 1979-1996.	1.1	43
40	FBXW7 is involved in Aurora B degradation. Cell Cycle, 2012, 11, 4059-4068.	1.3	43
41	Nuclear export regulation of COP1 by 14-3-3Ïƒ in response to DNA damage. Molecular Cancer, 2010, 9, 243.	7.9	40
42	CDK inhibitor p57^{Kip2}is negatively regulated by COP9 signalosome subunit 6. Cell Cycle, 2012, 11, 4633-4641.	1.3	38
43	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research, 2015, 75, 4131-4142.	0.4	38
44	Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biology and Therapy, 2008, 7, 1679-1684.	1.5	37
45	HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle, 2012, 11, 4181-4190.	1.3	37
46	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptorâ€“positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 63-72.	1.1	34
47	CDK inhibitor p57^{Kip2} is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle, 2013, 12, 935-943.	1.3	34
48	Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital. Journal of the Formosan Medical Association, 2015, 114, 742-749.	0.8	31
49	Regulating the stability and localization of CDK inhibitor p27^{Kip1} via CSN6-COP1 axis. Cell Cycle, 2015, 14, 2265-2273.	1.3	29
50	Tumor-Associated Microbiota in Esophageal Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 641270.	1.8	28
51	Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. Cell Cycle, 2006, 5, 1654-1661.	1.3	26
52	EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis. Advanced Science, 2020, 7, 2000681.	5.6	25
53	COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. Oncotarget, 2015, 6, 19721-19734.	0.8	25
54	Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer & Metabolism, 2013, 1, 21.	2.4	24

#	Article	IF	Citations
55	Farnesyltransferase inhibitors-induced autophagy: Alternative mechanisms?. Autophagy, 2009, 5, 129-131.	4.3	21
56	Factors associated with severity and mortality in patients with confirmed leptospirosis at a regional hospital in northern Taiwan. Journal of Microbiology, Immunology and Infection, 2020, 53, 307-314.	1.5	20
57	COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer. Oncotarget, 2015, 6, 28026-28041.	0.8	19
58	CSN6â€“TRIM21 axis instigates cancer stemness during tumorigenesis. British Journal of Cancer, 2020, 122, 1673-1685.	2.9	19
59	Desmosomal COP9 regulates proteome degradation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of Clinical Investigation, 2021, 131, .	3.9	18
60	Harness the functions of gut microbiome in tumorigenesis for cancer treatment. Cancer Communications, 2021, 41, 937-967.	3.7	18
61	Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth. Oncogene, 2004, 23, 7132-7143.	2.6	17
62	Aurora-B Kinase Inhibitors for Cancer Chemotherapy. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1514-1525.	1.1	17
63	CSN6 deregulation impairs genome integrity in a COP1-dependent pathway. Oncotarget, 2015, 6, 11779-11793.	0.8	16
64	DNA Damage-Mediated c-Myc Degradation Requires 14-3-3 Sigma. Cancer Hallmarks, 2013, 1, 3-17.	0.9	14
65	Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity. Journal of Cellular Biochemistry, 2006, 98, 128-138.	1.2	12
66	High Prevalence of Cardiometabolic Risk Factors in Hispanic Adolescents: Correlations with Adipocytokines and Markers of Inflammation. Journal of Immigrant and Minority Health, 2014, 16, 865-873.	0.8	12
67	Impact of diabetes on promoting the growth of breast cancer. Cancer Communications, 2021, 41, 414-431.	3.7	12
68	Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 61.	1.1	11
69	Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients. Cell Cycle, 2014, 13, 1299-1305.	1.3	11
70	CSN6-COP1 axis in cancer. Aging, 2015, 7, 461-462.	1.4	11
71	Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	10
72	CSN6 positively regulates c-Jun in a MEKK1-dependent manner. Cell Cycle, 2015, 14, 3079-3087.	1.3	10

#	Article	IF	Citations
73	Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth. Gastroenterology Report, 2020, 8, 261-276.	0.6	9
74	Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer. Journal of Ovarian Research, 2020, 13, 95.	1.3	8
75	Molecular targets for cell cycle inhibition and cancer therapy. Expert Opinion on Therapeutic Patents, 2003, 13, 329-346.	2.4	6
76	Ubiquitination-Mediated p57Kip2 Degradation by CSN5 Confers Cancer Cell Proliferation. Cancer Hallmarks, 2013, 1, 133-144.	0.9	6
77	Inhibitory Effects of the Extracts of Juglans sigillata Green Husks on the Proliferation, Migration and Survival of KYSE150 and EC9706 Human Esophageal Cancer Cell Lines. Nutrition and Cancer, 2019, 71, 149-158.	0.9	4
78	3,3â€²-Diindolylmethane Enhances Fluorouracil Sensitivity via Inhibition of Pyrimidine Metabolism in Colorectal Cancer. Metabolites, 2022, 12, 410.	1.3	4
79	Intercepting Akt with DNAzyme: a nasopharyngeal carcinoma story. Cancer Biology and Therapy, 2009, 8, 372-374.	1.5	1
80	Targeting hostâ€“microbe interaction in the mucus layer: a potential treatment option for diseases. Gastroenterology Report, 2019, 7, 1-2.	0.6	1
81	Discovery of Protein Degradation Machinery at the Desmosome Reveals Novel Triggers of the Desmosomal Disease, Arrhythmogenic Right Ventricular Cardiomyopathy. FASEB Journal, 2019, 33, 829.6.	0.2	1
82	C-type lectin receptors as potential targets for the treatment of gastrointestinal diseases related to fungal infection. Gastroenterology Report, 2019, 7, 376-377.	0.6	0
83	Functional Regulation of CIP/KIP CDK Inhibitors. Enzyme Inhibitors Series, 2006, , 29-53.	0.1	0
84	Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control. , 2010, , 69-80.		0
85	Roles of Negative and Positive Growth Regulators in Nasopharyngeal Carcinoma. , 2009, , 273-294.		0